The paper, published open access online in The Lancet Obstetrics, Gynaecology & Women's Health, highlights that 99m Tc-maraciclatide has potential as: A novel, non-invasive diagnostic test, particularly for superficial peritoneal endometriosis (SPE), which cannot be reliably detected by conventional imaging techniques and currently requires laparoscopic surgery for definitive diagnosis A tool to enable disease monitoring, eliminating uncertainty around disease recurrence A marker of treatment response, empowering the development of novel therapies 99m Tc-maraciclatide is a gamma-emitting radiotracer that binds to v3 integrin, which is upregulated during angiogenesis (new blood vessel formation), a cardinal feature of inflammatory diseases
[2] This 60% decline parallels the age-related decrease in wound healing capacity, collagen production, and tissue repair that characterizes biological aging, though causation has not been established
[13] Your exact dosage and frequency will be personalized
But price should be one factor among many, not the only factor